Skip to content

A randomized, double-blind, parallel controlled trial for San-Wei Qing-Zhi decoction in the treatment of hyperlipidemia

A randomized, double-blind, parallel controlled trial for San-Wei Qing-Zhi decoction in the treatment of hyperlipidemia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025639
Enrollment
Unknown
Registered
2019-09-03
Start date
2019-09-10
Completion date
Unknown
Last updated
2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipemia

Interventions

Sponsors

Ningjin County Hospital, Xingtai City, Hebei province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) low-density lipoprotein (ldl-c) >=3.4mmol/L; (2) meet the diagnostic criteria of TCM syndrome of mutual phlegm and blood stasis syndrome (score >=6 points); (3) outpatient or inpatient male and female patients aged 18-70 years; (4) sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) pregnant or lactating women and allergic conditions (allergic to 2 or more foods, drugs or other substances such as paint and pollen); (2) patients with acute myocardial infarction, cerebrovascular accident, severe trauma or major surgery within half a year; (3) secondary hyperlipidemia (by systemic diseases such as diabetes, nephrotic syndrome, hypothyroidism, kidney failure, liver disease, systemic lupus erythematosus (sle), glycogen storage disease, multiple myeloma, fat atrophy, acute porphyrin disease, such as polycystic ovary syndrome, or by certain drugs, such as diuretics, glucocorticoid, beta blockers such as cause dyslipidemia); (4) patients with sugar metabolic abnormalities (I diabetes, II of poorly controlled diabetes, fasting plasma glucose or greater tendency for 10.0/L, HbA1c >8.0%); (5) patients with severe primary diseases including liver, kidney and hematopoietic system; (6) mental patients; (7) familial hypercholesterolemia; (8) those taking part in other drug tests.

Design outcomes

Primary

MeasureTime frame
low density lipoprotein;

Secondary

MeasureTime frame
triglyceride;total cholesterol;high-density lipoprotein ;very low density lipoprotein;TCM syndrome scale;

Countries

China

Contacts

Public ContactJunhua Zhang

Evidence-Based Medicine Center of Tianjin University of Traditional Chinese Medicine

zjhtcm@foxmail.com+86 13902020873

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026